摘要
目的分析曲妥珠单抗同时联合蒽环、紫杉类药物应用于Her-2阳性乳腺癌新辅助治疗的疗效。方法30例Her-2阳性呵手术的乳腺癌患者，给予4周期ATH序贯2～4周期TH新辅助治疗，治疗后行乳腺癌改良根治术或保乳术，结果进行统计分析。结果30例入组患者，完全缓解（Com—pleteremission，CR）和部分缓解（Partialremission，PR）的患者共25例（80．0％），其中CR的7例（23．3％），无疾病进展（Progressiondisease，PD）病例；病理完全缓解（Pathologicalcompleteresponse，pCR）15例（50．O％）。结论对于Her-2阳性的乳腺癌患者给予含蒽环、紫杉类及曲妥珠单抗的新辅助治疗，可以达到较高的临床获益率和病理学完全缓解率，不良反应可以耐受。
Objective To study a retrospective analysis of the clinical effect of the neoadjuvant therapy of treating Her - 2 positive breast cancer by applying Trastuzumab together with atbracyclines and taxane - based chemotherapy. Methods 30 patients with Her - 2 positive operable breast cancer were accepted 4 cycles ATH which were followed by 2 -4 cycles TH regimen neoadjuvant chemotherapy before modified radical mastectomy or conserving surgery. Then a statistical analysis was made. Results Among the 30 concerned patients, 25 （ 80% ） reached completly remissio and Partial remission, and 15 （50%）obtained pathological complete remission. Con- clusion A complete pathological remission as well as a considerably high clinical benefit ratio can be achieved by treating Her - 2 positive breast cancer with Trastuzumab together with athracyclines and taxane - based chemo- therapy. Adverse reaction is tolerable.
出处
《实用肿瘤学杂志》
CAS
2013年第2期97-100,共4页
Practical Oncology Journal
基金
国家863计划重大项目分课题（2006AA02A246）
